A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Summary

The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) and are receiving chemotherapy. Researchers also want to learn about the remission rates (rates of recovery) in patients with cancer who have received treatment with epoetin alfa. The safety and effectiveness of this therapy will also be studied.

Timeline

Start

2008-03

Primary completion

2013-06

Completion

2013-06

Drugs

Indications